Suppliers and packagers for FASLODEX

FASLODEX

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Astrazeneca	FASLODEX	fulvestrant	SOLUTION;INTRAMUSCULAR	021344	NDA	AstraZeneca Pharmaceuticals LP	0310-0720-10	2 SYRINGE, GLASS in 1 CARTON (0310-0720-10) / 5 mL in 1 SYRINGE, GLASS	2010-11-01

Fulvestrant (FASLODEX) Active Pharmaceutical Ingredient Suppliers

Last updated: February 19, 2026

This report analyzes the landscape of active pharmaceutical ingredient (API) suppliers for fulvestrant, the API in AstraZeneca's blockbuster breast cancer drug FASLODEX. The analysis focuses on identifying key manufacturers, their geographic distribution, regulatory standing, and potential supply chain risks for generic developers and investors.

Who are the Primary API Manufacturers for Fulvestrant?

The manufacturing of fulvestrant API is concentrated among a limited number of specialized chemical companies. These entities typically possess the complex synthetic capabilities required for steroidal hormone synthesis. While AstraZeneca maintains proprietary control over its finished drug product, the API itself is sourced from third-party manufacturers who must adhere to stringent Good Manufacturing Practices (GMP) regulations.

Key manufacturers identified in publicly available patent filings, regulatory documents, and industry databases include:

• Divi's Laboratories Limited: An India-based pharmaceutical company with significant expertise in complex API synthesis. Divi's is known for its large-scale manufacturing capabilities and has a strong track record in supplying APIs for various therapeutic areas.
• Sun Pharmaceutical Industries Ltd.: Another major Indian pharmaceutical producer. Sun Pharma has a broad API portfolio and a global regulatory presence, including approvals from major health authorities.
• IOL Chemicals and Pharmaceuticals Limited: An Indian manufacturer of bulk drugs and specialty chemicals. IOL has demonstrated capabilities in producing steroidal APIs.
• Neuland Laboratories Limited: Based in India, Neuland is a contract development and manufacturing organization (CDMO) with expertise in complex organic synthesis and regulatory compliance.
• Bristol-Myers Squibb Company: While primarily known as a finished drug producer, BMS has been identified in some patent literature as a potential or historical manufacturer or processor of fulvestrant intermediates or API.

The supply chain for fulvestrant API is characterized by a reliance on manufacturers with specific expertise in steroid chemistry, which is a niche area within API production.

What is the Geographic Distribution of Fulvestrant API Manufacturing?

The manufacturing of fulvestrant API is heavily concentrated in India. This aligns with the broader trend of global pharmaceutical API production, where India has emerged as a dominant force due to its cost-effectiveness, skilled workforce, and established regulatory framework for API manufacturing.

• India: Dominant supplier, hosting multiple key manufacturers such as Divi's Laboratories, Sun Pharma, IOL Chemicals and Pharmaceuticals, and Neuland Laboratories. These companies benefit from robust chemical manufacturing infrastructure and expertise in complex synthesis.
• Other Regions: While the bulk of primary API synthesis occurs in India, some intermediates or downstream processing may occur in other regions, including Europe and North America, often by contract manufacturing organizations. However, the core synthesis of the fulvestrant molecule is predominantly an Indian manufacturing strength.

The geographic concentration in India presents both opportunities and risks. While it offers economies of scale and competitive pricing, it also introduces potential vulnerabilities related to geopolitical stability, trade policies, and supply chain disruptions originating from that region.

What is the Regulatory Status of Key API Suppliers?

Suppliers of fulvestrant API must comply with the regulatory requirements of the target markets where the finished drug product will be sold. For generic drug developers seeking to launch in the United States or Europe, this typically means having APIs manufactured in facilities inspected and approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Key regulatory considerations include:

• FDA Approval: Facilities manufacturing fulvestrant API for the U.S. market must be inspected and approved by the FDA. This involves rigorous review of manufacturing processes, quality control systems, and compliance with Current Good Manufacturing Practices (cGMP).
• EMA Approval: Similarly, for the European market, API manufacturers must demonstrate compliance with EU GMP standards, often confirmed through inspections by national competent authorities within the EU and documented in Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP).
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. These confidential documents provide detailed information about the manufacturing process, facilities, and quality control of the API. Generic drug applicants reference these DMFs in their Abbreviated New Drug Applications (ANDAs).

While specific DMF filings are confidential, the ability of major Indian API manufacturers like Divi's Laboratories and Sun Pharma to supply global markets indicates their established regulatory compliance and consistent quality standards. The absence of a major supplier from a regulatory sanction list is a critical factor for generic manufacturers.

What are the Patent Expirations and Generic Entry Timelines?

The patent landscape for FASLODEX (fulvestrant) is a critical determinant for generic manufacturers. The primary composition of matter patent for fulvestrant has expired, opening the door for generic competition. However, secondary patents related to formulations, methods of treatment, or manufacturing processes can create additional layers of intellectual property protection that generic developers must navigate.

• Composition of Matter Patent Expiration: The foundational patent for fulvestrant has expired, allowing for the development of generic versions.
• Secondary Patents: AstraZeneca has historically pursued and been granted secondary patents covering aspects such as specific salt forms, polymorphs, or novel formulations that could extend market exclusivity. Generic developers must carefully analyze these patents to ensure their proposed product does not infringe.
• Generic Approvals: The U.S. FDA has approved several generic versions of fulvestrant. For example, Mylan (now Viatris) received approval for its generic fulvestrant product. The timelines for these approvals indicate that the regulatory pathway for generic fulvestrant is well-established.
• Market Entry: With regulatory approvals in place and key patents expired, generic fulvestrant is available in key markets, leading to price competition.

The timing of generic entry is a direct function of patent expiry and the ability of generic companies to successfully file ANDAs, which requires a reliable and compliant API source.

What are the Potential Supply Chain Risks for Fulvestrant API?

The reliance on a concentrated geographic region for API manufacturing and the complex nature of steroidal synthesis introduce specific supply chain risks for fulvestrant.

• Geopolitical and Trade Risks: Concentration of manufacturing in India subjects the supply chain to potential disruptions from trade disputes, tariffs, or political instability in the region.
• Regulatory Scrutiny and Compliance: API manufacturers must maintain high standards of GMP compliance. Any regulatory action against a key supplier (e.g., FDA warning letters, import alerts) can significantly disrupt supply.
• Quality Control and Batch-to-Batch Consistency: The complex synthesis of fulvestrant requires stringent quality control. Any deviation can lead to batch failures, impacting availability and potentially requiring costly investigations and remediation.
• Raw Material Sourcing: The synthesis of fulvestrant relies on specific starting materials and intermediates. Disruptions in the supply of these upstream components can cascade down to API availability.
• Capacity Constraints: As demand for generic fulvestrant grows, capacity constraints at key API manufacturing sites could become a factor, particularly if only a few manufacturers possess the specialized capabilities and regulatory approvals.
• Counterfeit and Substandard Products: While less common for regulated APIs, the risk of counterfeit or substandard API entering the supply chain always exists and requires robust supplier qualification processes.

Generic manufacturers and their investors must conduct thorough due diligence on potential API suppliers, assessing not only their manufacturing capabilities and regulatory history but also their risk mitigation strategies.

How Do Fulvestrant API Prices Compare?

Pricing for fulvestrant API is influenced by manufacturing complexity, regulatory compliance costs, economies of scale, and competitive dynamics among suppliers. While specific pricing data is proprietary and fluctuates, general trends can be inferred.

• Manufacturing Costs: The multi-step synthesis of fulvestrant, involving steroid chemistry, is inherently more complex and costly than that of small molecule APIs. This contributes to a higher baseline API price.
• Competition: The entry of generic versions of FASLODEX has increased competition among API suppliers. This competitive pressure drives down API prices from their peak levels during the branded drug's exclusivity period.
• Supplier Location: API suppliers based in India generally offer more competitive pricing due to lower labor and operational costs compared to manufacturers in Western countries, while still meeting global regulatory standards.
• Volume and Contractual Agreements: Large-volume contracts typically secure more favorable pricing. Long-term supply agreements can also lock in prices, offering stability to generic drug manufacturers.

Generic API prices for fulvestrant are significantly lower than the cost of branded FASLODEX. However, the API cost remains a substantial component of the overall manufacturing cost for generic fulvestrant products.

What is the Outlook for Fulvestrant API Supply?

The outlook for fulvestrant API supply is generally stable, supported by established manufacturing capabilities and ongoing demand for both branded and generic products.

• Continued Demand: Fulvestrant remains a critical treatment option for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. Demand is expected to persist, driven by its established efficacy.
• Generic Market Growth: The increasing availability of generic fulvestrant is likely to drive down overall healthcare costs, potentially increasing patient access and overall unit volume, although not necessarily total revenue for API suppliers.
• Supplier Landscape: The current supplier base, dominated by experienced Indian manufacturers, is well-positioned to meet demand. However, potential disruptions or increased regulatory hurdles could shift market dynamics.
• Technological Advancements: While fulvestrant is a mature molecule, ongoing efforts in process optimization by API manufacturers could lead to incremental improvements in cost-efficiency and yield, further stabilizing supply.

Generic manufacturers should prioritize securing supply agreements with multiple qualified API suppliers to mitigate risks and ensure continuity of supply. Long-term relationships with these suppliers, built on trust and consistent performance, are crucial.

Key Takeaways

• Fulvestrant API manufacturing is concentrated among a select group of specialized chemical companies, primarily located in India.
• Key suppliers include Divi's Laboratories, Sun Pharmaceutical Industries, IOL Chemicals and Pharmaceuticals, and Neuland Laboratories, all of whom must maintain stringent GMP compliance for FDA and EMA approval.
• The patent expiry for the composition of matter of fulvestrant has enabled generic entry, with several generic versions already approved and marketed.
• Supply chain risks include geopolitical factors, regulatory compliance issues, quality control challenges, and potential raw material sourcing disruptions, with the concentration of manufacturing in India being a significant consideration.
• Fulvestrant API pricing is influenced by manufacturing complexity, competition from generic suppliers, and economies of scale, with Indian manufacturers typically offering more competitive pricing.
• The outlook for fulvestrant API supply is stable due to continued demand and established manufacturing capacity, but diversification of suppliers is recommended for risk mitigation.

FAQs

1. Are there any critical quality attributes unique to fulvestrant API that manufacturers must control? Yes, as a steroidal compound, fulvestrant API requires precise control over stereochemistry, purity, and impurity profiles. Specific polymorphic forms and crystalline structures can also impact bioavailability and stability, necessitating rigorous control during the crystallization and finishing steps of API manufacturing.

2. What is the typical lead time for securing a new supply agreement for fulvestrant API? Securing a new supply agreement for fulvestrant API typically involves a comprehensive supplier qualification process. This includes auditing manufacturing facilities, reviewing quality systems, and potentially conducting pilot batches. Lead times can range from six to twelve months, depending on the existing relationships and the thoroughness of the qualification process.

3. What are the major regulatory hurdles that new entrants face in becoming fulvestrant API suppliers? New entrants must establish GMP-compliant manufacturing facilities, obtain necessary environmental and safety permits, and successfully undergo inspections by major regulatory bodies like the FDA and EMA. They must also prepare and file a robust Drug Master File (DMF) that details their manufacturing process, quality control measures, and stability data.

4. How does the market penetration of generic fulvestrant impact the demand for the API? The market penetration of generic fulvestrant has increased overall demand for the API. While generic competition drives down the price of the finished drug product, the increased accessibility and use by a larger patient population translate into a higher volume of API required by the market.

5. What are the implications of a single API supplier facing a significant regulatory action (e.g., FDA warning letter)? A significant regulatory action against a major fulvestrant API supplier could lead to immediate supply shortages. Generic drug manufacturers relying on that supplier would need to quickly qualify alternative sources, which can be a time-consuming and complex process. This highlights the importance of dual sourcing strategies for critical APIs.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Drugs@FDA. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/ [2] European Medicines Agency. (n.d.). European public assessment reports (EPARs). Retrieved from https://www.ema.europa.eu/en/medicines/human/referral/faslodex [3] Patent databases (e.g., Google Patents, USPTO, Espacenet) for fulvestrant patents and their expiry dates. [4] Industry analysis reports on the pharmaceutical API market. [5] Company annual reports and investor presentations of major API manufacturers (e.g., Divi's Laboratories, Sun Pharma).